Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series
| Autor: | Avinash Kulkarni, Alexander Spratt, Roberto dell'Omo, Catey Bunce, Aachal Kotecha, L. Ogunbowale, Wendy A. Franks |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A Intraocular pressure Visual acuity genetic structures Visual Acuity Glaucoma Iris Angiogenesis Inhibitors Adult Aged Aged 80 and over Antibodies Monoclonal Antibodies Monoclonal Humanized Antihypertensive Agents Bevacizumab Female Follow-Up Studies Glaucoma Neovascular Humans Intraocular Pressure Intravitreal Injections Middle Aged Neovascularization Pathologic Pain Pain Measurement Prospective Studies Recurrence Tonometry Ocular Treatment Outcome Young Adult Ophthalmology Interquartile range Monoclonal 80 and over Medicine Prospective cohort study Humanized Neovascular medicine.symptom Ophthalmologic Surgical Procedure medicine.drug medicine.medical_specialty Antibodies Tonometry Ocular Neovascularization Pathologic Rubeosis iridis business.industry medicine.disease eye diseases Surgery sense organs business |
| Zdroj: | Archives of ophthalmology (Chicago, Ill. : 1960). 129(2) |
| ISSN: | 1538-3601 |
| Popis: | To examine the efficacy of intravitreal bevacizumab for pain relief in eyes with refractory neovascular glaucoma.In this prospective case series, 52 eyes with neovascular glaucoma were administered intravitreal bevacizumab, 1.25 mg, and monitored for 6 months. The primary outcome measure was change in subjective pain score. Intraocular pressure and iris neovascularization were evaluated at each visit. Surgical intervention for control of intraocular pressure was performed according to clinical need.Forty-two patients (44 eyes) completed the 6-month follow-up. Subjective pain score was reduced significantly 1 week after intravitreal bevacizumab injection and lasted throughout the follow-up period (median [interquartile range]: baseline, 3 [0-6]; week 1, 1 [0-3]; month 1, 0 [0-1]; month 3, 0 [0-1]; and month 6, 0 [0-0]; Kruskal-Wallis χ(2) 31.03; P .001). A rapid, yet relatively transient, reduction in iris neovascularization was also noted (iris neovascularization grade at baseline, 4.0 [3-4]; week 1, 2.5 [1-4]; month 1, 2.0 [1-4]; month 3, 3.0 [2-4]; and month 6, 3.0 [2-4], χ(2) 23.33; P .001). Four eyes (8%) required more than 1 injection to facilitate further intraocular surgery.Intravitreal bevacizumab is a useful adjunct in the management of refractory neovascular glaucoma, producing rapid relief of pain. However, we found no evidence to suggest that intravitreal bevacizumab lowers intraocular pressure in eyes with angle closure; conventional medical, laser, and surgical treatment are still needed in these eyes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|